Abstract
A follow-up study has been carried out to assess the association between MTHFR polymorphisms (SNPs) and overall survival (OS) of colorectal cancer (CRC) patients. Data on 411 CRC patients after surgery were tested for the MTHFR 677C > T and 1298A > C polymorphisms. For MTHFR C677T, patients with CT genotype (HR = 1.17; 95 % CI 0.77–1.80) and those with TT genotype (HR = 1.09; 95 % CI 0.67–1.75) had no statistically significant greater risk of dying than those with wild-type genotype. For MTHFR A1298C, the HRs of AC and CC genotype were 1.09 (95 % CI 0.75–1.59) and 0.79 (95 % CI 0.48–1.29) comparing with AA genotype. In the subgroup, 183 patients received chemotherapy treatment, and the HRs of patients with CT and TT genotype were 0.93 (95 % CI 0.50–1.72) and 0.86 (95 % CI 0.44–1.68) for MTHFR C677T. For A1298C polymorphism, AC genotype (HR = 1.39; 95 % CI 0.81–2.39) and CC genotype (HR = 1.22; 95 % CI 0.75–2.00) did not show significant differences. In conclusions, no significant association was observed between the 677C > T and 1298A > C polymorphisms of MTHFR and the prognosis of colorectal cancer patients with curative resection, including all the subjects and the subgroup of chemotherapy.
This is a preview of subscription content, log in via an institution to check access.
References
WHO. Globocan 2008 (IARC), Section of cancer information. September 14, 2012. Available at: http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66.
Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111–3.
Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab. 1998;64:169–72.
Huang Y, Han S, Li Y, Mao Y, Xie Y. Different roles of MTHFR C677T and A1298C polymorphisms in colorectal adenoma and colorectal cancer: a meta-analysis. J Hum Genet. 2007;52:73–85.
Etienne MC, Formento JL, Chazal M, Francoual M, Magne N, Formento P, et al. Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics. 2004;14:785–92.
Zhang W, Press OA, Haiman CA, Yang DY, Gordon MA, Fazzone W, et al. Association of methylenetetrahydrofolate reductase gene polymorphisms and sex-specific survival in patients with metastatic colon cancer. J Clin Oncol. 2007;25:3726–31.
Wisotzkey JD, Toman J, Bell T, Monk JS, Jones D. MTHFR (C677T) polymorphisms and stage III colon cancer: response to therapy. Mol Diagn. 1999;4:95–9.
Marcuello E, Altes A, Menoyo A, Rio ED, Baiget M. Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy? Cancer Chemother Pharmacol. 2006;57:835–40.
Afzal S, Jensen SA, Vainer B, Vogel U, Matsen JP, Sorensen JB, et al. MTHFR polymorphisms and 5-Fu-based adjuvant chemotherapy in colorectal cancer. Ann Oncol. 2009;20:1660–6.
Acknowledgments
This study was supported by grants from Harbin city science and technology innovation talent research of special fund project (2011RFXXS045) and National Natural Science Foundation of China for Priority Areas (NSFC 30972539).
Conflict of interest
None of the authors had any conflicts of interest.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Zhu, L., Wang, F., Hu, F. et al. Association between MTHFR polymorphisms and overall survival of colorectal cancer patients in Northeast China. Med Oncol 30, 467 (2013). https://doi.org/10.1007/s12032-013-0467-1
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12032-013-0467-1